Johnson & Johnson Q3 2026 Financial Report

Source link: Johnson & Johnson Q3 2026 Financial Report. Adjusted EPS: Actual………… $2.59; Forecast………… $2.53. Quarterly Revenue: Actual………… $25.4 billion; Forecast……….. $25.38 billion. Johnson & Johnson, together with its subsidiaries, engages in research and development, manufacturing, and sale of a wide range of health care products worldwide. The company operates in two segments […] site

Actual Earnings Per Share (EPS)…………. $2.59 Forecast………… $2.53 Actual Quarterly REVENUE………… $25.4 Billion Forecast……….. 25.38 Billion Report Q3 2026 UnitedHealth Company Earnings Per Share (EPS) Actual…………. 4.69 Forecast………… 4.12 Real Quarterly Revenue (REVENUE)………… 112.7 Billion USD Forecast……….. 111.31 Billion Dollar United Company 10-year Treasury bond yield at 5.9%; The point of change of investors to bonds? The Bank of America (BofA) October survey of fund managers shows that investors are the most overweight to technology stocks since August 2020, the allocation of major American banks on the eve of the release of financial reports; Interest rates and lending prospects under the microscope The third quarter financial reports of major American banks are published this week, in a situation where the increase in the yield of treasury bonds, the possibility of the Kremlin calling Europe's criticism of Trump's agreement on Russian diesel as hypocritical. Concerns about Chinese competitors and doubts about the artificial intelligence boom of the global memory chip market were met with a new wave of selling in trading on Tuesday; Get informed about the news by subscribing to the YouTube and Times newsletter.

Johnson & Johnson, together with its subsidiaries, operates in the field of research and development, production and sales of various health products around the world. The company operates in two main sectors: Innovative Medicine and Medical Technologies.